KDR and metabolic dysfunction-associated steatohepatitis: Yang et al. [48] have also shown that in addition to the decreasing fibrosis, portal hypertension, and angiogenesis, the anti-VEGFR action of sorafenib improves the hepatic blood flow and inhibits the activation of leukocytes, the accumulation of splanchnic blood, and the formation ascites in NASH cirrhotic rats.